Material Insights · Understanding the Material World

Insulin medicines: Supply chain

Output and value

World output and its value, with year and source

MeasureValueUnitYearSource
Novo Nordisk sales of insulin (one company's sales, not world output)53,137DKK million2025[12]
Sanofi net sales of Lantus (insulin glargine; one company's sales; table value, Appendix 1 net sales table)1733EUR million2025[13]
Sanofi net sales of Toujeo (insulin glargine; one company's sales; table value, Appendix 1 net sales table)1345EUR million2025[13]

as of 2026-11-13

Where it is made

Country shares of world output

CountryMeasureYearSource
IndiaA press report says Wockhardt sells human insulin in India and exports it to around ten countries, and Biocon, Eris and Lupin sell lower-cost glargine in India; no country shares of world output were found2026[10]
MalaysiaBiocon has invested $600 million since 2011 in its Johor plant, as reported2026[10]

as of 2026-11-13

Main companies

The largest makers and their shares

CompanyCountryShareMeasureYearSource
Novo NordiskDenmark– Insulin sales of DKK 53,137 million in 2025 (one company's sales); headquarters in Bagsværd, Denmark2025[12]
SanofiFrance– Lantus €1,733 million and Toujeo €1,345 million net sales in 2025 (table values); global headquarters in Paris2025[13][19]
Eli Lilly and CompanyUnited States of America– Began selling Iletin in 1923, in Indianapolis, Indiana; no insulin sales figure found in a source opened1923[3][4]
Eris LifesciencesIndia24Share of India's regular human insulin cartridge market, up from 13% over FY26, as Eris told investors (the company's own figure, reported in the press; one segment); registered office in Ahmedabad2026[10][20]

as of 2026-11-13

Supply chains of the main makers

For the top three to five producing countries and India: share, where inputs and components come from, main makers and how variants differ

CountryInputs fromMakersHow variants differYearSource
IndiaNot stated in the pages openedBiocon, Eris and Lupin (lower-cost glargine); Wockhardt (human insulin, exported to about ten countries); Novo Nordisk, which a press report says told its marketing partner Abbott India that human insulin in Penfill cartridges and FlexPen devices would be withdrawn once stock ran out; Sanofi's Lantus remains the reference basal insulinHuman insulin such as Human Mixtard is under price control, the report says; the once-weekly analogue Awiqli is on sale2026[10]

as of 2026-11-13

Industries that make it

The industries and kinds of firm that make it

Made by

as of 2026-11-13

Rules and standards

Labels, efficiency and emission standards, producer responsibility, bans and tariffs

RulePlaceYearWhat it doesSource
NPPA ceiling prices for human insulin injections (price fixation orders S.O. 2734(E) and 2735(E))India2012Government review orders confirm that the NPPA orders of 16 November 2012 fixed ceiling prices for human insulin injections [18]; a press report says the ceiling applied irrespective of brand, with separate ceilings for domestic and imported insulin, and that Biocon and Wockhardt objected to the higher ceiling for imports [11][18][11]
Price control on human insulin, such as Human MixtardIndia2026A 2026 press report says Human Mixtard sits under price control and earns close to Rs 800 crore a year[10]
WHO prequalification of human insulin (pilot procedure)World2022WHO prequalified the first human insulins on 28 September 2022; full assessment includes WHO inspection of the relevant manufacturing facilities[7][8]

as of 2026-11-13

India

India's output, trade, makers and rules in a short paragraph

About 6 million people in India were on insulin therapy in 2026, a press report says [10]. Biocon, Eris and Lupin sell lower-cost glargine and Wockhardt sells human insulin; the report says Novo Nordisk is withdrawing human insulin in Penfill cartridges and FlexPen devices [10]. NPPA orders of November 2012 fixed ceiling prices for human insulin injections [18][11], and Human Mixtard is under price control [10]. No source opened gives India's output, trade or import share.

as of 2026-11-13

Trade

World exports, the top exporters and importers and India, from UN Comtrade by HS code (worked out by the site)

FlowValueUnitVolumeUnitYearSource
World exports5.28USD billion23.3thousand tonnes2024UN Comtrade, HS 3004.31
Average export value (calculated)226.9USD per kg– – 2024UN Comtrade, HS 3004.31
Exporter: Germany (40.9% of world exports)2.16USD billion1.5thousand tonnes2024UN Comtrade, HS 3004.31
Exporter: France (29.3% of world exports)1.55USD billion7.4thousand tonnes2024UN Comtrade, HS 3004.31
Exporter: United States (9.8% of world exports)0.52USD billion1.4thousand tonnes2024UN Comtrade, HS 3004.31
Exporter: India (2.8% of world exports)0.15USD billion2.6thousand tonnes2024UN Comtrade, HS 3004.31
Exporter: Hungary (2.1% of world exports)0.11USD billion0.6thousand tonnes2024UN Comtrade, HS 3004.31
India exports (rank 4, 2.8% of world)0.15USD billion2.6thousand tonnes2024UN Comtrade, HS 3004.31
India imports (rank 7, 2.9% of world)0.19USD billion0.9thousand tonnes2024UN Comtrade, HS 3004.31
Importer: United States (14.8% of world imports)0.95USD billion5.2thousand tonnes2024UN Comtrade, HS 3004.31
Importer: Germany (12.3% of world imports)0.79USD billion1.8thousand tonnes2024UN Comtrade, HS 3004.31
Importer: France (6.5% of world imports)0.42USD billion1.9thousand tonnes2024UN Comtrade, HS 3004.31

Worked out from data

Sources

  1. New WHO report maps barriers to insulin availability and suggests actions to promote universal access World Health Organization, 2021, news item of 12 November 2021
  2. Insulin Development and Commercialization American Chemical Society (National Historic Chemical Landmark), 2023, landmark booklet, © 2023 American Chemical Society
  3. Manufactured insulin, 'Iletin', United States, 1923 | Science Museum Group Collection Science Museum Group, object record co143500
  4. First human insulins prequalified World Health Organization, Prequalification of Medical Products, 2022, news item of 28 September 2022
  5. Human Insulin | WHO - Prequalification of Medical Products World Health Organization, Prequalification of Medical Products, prequalification page for human insulin; the page shows no start date for the pilot
  6. India 2030: Who Supplies the Next 10 Million? BioSpectrum India (Ankit Kankar), 2026, article of 1 November 2026
  7. 1 insulin price cap for all brands Business Standard (Sushmi Dey), 2012, article of 21 November 2012
  8. Financial performance - Novo Nordisk Annual Report 2025 Novo Nordisk, 2025, insulin sales sentence; page footer gives Novo Nordisk HQ, Novo Alle 1, 2880 Bagsværd, Denmark
  9. 2025: strong sales and EPS growth. Sanofi, 2026, full-year 2025 results press release, Paris, January 29, 2026; Appendix 1, FY 2025 net sales table
  10. Review orders on the review applications of M/s Eli Lilly & Co. (India) Pvt. Ltd. against NPPA price fixation orders for insulin (File No. 31015/17/2012-PI.I and others) Government of India, Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals, 2013, order of 15 January 2013 on S.O. 2734(E) and 2735(E); the document gives no price amounts
  11. Press Release: Sanofi moves into its new Paris global headquarters Sanofi, 2022, press release of 28 November 2022
  12. Outcome of the board meeting held today, i.e., Wednesday, November 12, 2025 Eris Lifesciences Limited (filing to the National Stock Exchange of India), 2025, letterhead: Registered & Corporate Office, Bodakdev, Ahmedabad